Advances in the identification and localization of the abnormal genes in the multiple endocrine neoplasia syndromes have provided Mew methods of identifying ''at risk'' individuals in these families. Genetic testing using linkage analysis in multiple endocrine neoplasia (MEN) 1 and direct mutation analysis of the RET protooncogene in MEN 2 is MOW available for these disorders. New management issues for these disorders have resulted and a practical approach to these issues is discussed.